6. Meta‐regression for ACR50 response.
| MODEL FIT | ||||||||
| Beta coefficient, median (CrI) | Interpretation | Unadjusted analysis | Adjusted analysis | |||||
| DIC | Between‐study standard deviation | Total residual deviance (number of parameters) | DIC | Between‐study standard deviation | Total residual deviance (number of parameters) | |||
| MTX‐naïve | ||||||||
| MTX response rate | ‐1.7 (‐4.3 to 1.3) | Decrease in OR of 0.85 times (0.65 to 1.14) for every 10% increase in the response rate for MTX | 609.2 | 0.19 | 64.8 (64) | 610.9 | 0.21 | 64.6 (64) |
| Disease duration (years) | 0.008 (‐0.08 to 0.12) | Increase in OR of 1.01 times (0.92 to 1.12) for every year of disease duration | 585.1 | 0.21 | 61.5 (62) | 585.3 | 0.25 | 61.0 (62) |
| Duration of trial (weeks) | ‐0.002 (‐0.01 to 0.007) | Decrease in OR of 0.97 times (0.87 to 1.1) for every 12 weeks of trial duration | 609.2 | 0.19 | 64.8 (64) | 609.2 | 0.23 | 63.6 (64) |
| MTX dose >= 15 mg/week | ‐0.34 (‐0.80 to 0.03) | Decrease in OR of 0.71 times (0.45 to 1.0) for trials where the dose of MTX is >= 15 mg/wk | 609.2 | 0.19 | 64.8 (64) | 606.9 | 0.17 | 63.6 (64) |
| Year of publication of trial | 0.049 (0.008 to 0.10) | Increase in OR of 1.05 times (1.01 to 1.11) for each year later of publication (range of years 2000‐2015) | 609.2 | 0.19 | 64.8 (64) | 605.4 | 0.13 | 61.2 (64) |
| Swollen joint count | ‐0.04 (‐0.12 to 0.03) | Decrease in OR of 0.96 times (0.89 to 1.03) for every 1 additional swollen joint at baseline | 396.8 | 0.30 | 40.4 (40) | 396.4 | 0.23 | 40.3 (40) |
| DAS‐28 | 0.57 (‐0.29 to 1.6) | Increase in OR of 1.8 times (0.74 to 5.2) for every 1 additional point increase in DAS28 at baseline | 407.1 | 0.13 | 38.9 (40) | 407.6 | 0.12 | 38.2 (40) |
| MTX‐inadequate response | ||||||||
| MTX response rate | ‐5.3 (‐8.5 to ‐2.8) | Decrease in OR of 0.59 times (0.43 to 0.75) for every 10% increase in the response rate for MTX | 818.9 | 0.24 | 104.7 (97) | 825.3 | 0.24 | 105.1 (97) |
| Disease duration (years) | 0.10 (0.02 to 0.19) | Increase in OR of 1.11 times (1.02 to 1.21) for every year of disease duration | 740.4 | 0.27 | 91.9 (87) | 736.7 | 0.21 | 91.1 (87) |
| Duration of trial (weeks) | 0.001 (‐0.02 to 0.02) | Increase in OR of 1.02 times (0.83 to 1.22) for every 12 weeks of trial duration | 818.9 | 0.24 | 104.7 (97) | 819.3 | 0.26 | 104.0 (97) |
| MTX dose >= 15 mg/week | ‐0.17 (‐0.53 to 0.20) | Decrease in OR of 0.85 times (0.59 to 1.22) for trials where the dose of MTX is >= 15 mg/wk | 818.9 | 0.24 | 104.7 (97) | 818.3 | 0.27 | 102.4 (97) |
| Year of publication of trial | ‐0.03 (‐0.08 to 0.01) | Decrease in OR of 0.97 times (0.93 to 1.01) for each year later of publication (range of years 2000‐2015) | 818.9 | 0.24 | 104.7 (97) | 819.5 | 0.21 | 105.5 (97) |
| Swollen joint count | 0.02 (‐0.05 to 0.08) | Increase in OR of 1.02 times (0.95 to 1.09) for every 1 additional swollen joint at baseline | 728.0 | 0.26 | 92.0 (87) | 727.3 | 0.27 | 91.8 (87) |
| DAS‐28 | 0.23 (‐0.31 to 0.79) | Increase in OR of 1.26 times (0.73 to 2.20) for every 1 additional point increase in DAS28 at baseline | 546.7 | 0.25 | 71.1 (64) | 548.3 | 0.27 | 71.1 (64) |
Abbreviations: DAS: Disease Activity Score; DIC, deviance information criterion; IM, intra‐muscular; IV, intravenous; MD, mean difference; MTX, methotrexate; NE, not estimable; OR, odds ratio; sc, subcutaneous.